Literature DB >> 12168556

Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention.

Gustavo C Román1.   

Abstract

VaD is the second most common cause of dementia in the elderly after AD. VaD is defined as the loss of cognitive function resulting from ischemic, ischemic-hypoxic, or hemorrhagic brain lesions as a result of CVD and cardiovascular pathologic changes. Diagnosis requires (1) cognitive loss (often predominantly subcortical), (2) vascular brain lesions demonstrated by imaging, and (3) exclusion of other causes of dementia, such as AD. VaD is excluded by brain imaging showing no evidence of vascular lesions. VaD may be caused by multiple strokes (MID or poststroke dementia) but also by single strategic strokes, multiple lacunes, and hypoperfusive lesions such as border zone infarcts and ischemic periventricular leukoencephalopathy (Binswanger's disease). Primary and secondary prevention of stroke and cardiovascular disease decreases the burden of VaD. Genetic advice is needed in patients with familial forms, such as CADASIL. Treatment involves control of risk factors (i.e., hypertension, diabetes, smoking, hyperfibrinogenemia, hyperhomocystinemia, orthostatic hypotension, cardiac arrhythmias). Anticholinergic medications used for AD are also useful in VaD, and atypical antipsychotic agents and antidepressants (e.g., selective serotonin reuptake inhibitors) may be required in some patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168556     DOI: 10.1016/s0025-7125(02)00008-1

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  42 in total

Review 1.  Vascular aspects of cognitive impairment and dementia.

Authors:  Maximilian Wiesmann; Amanda J Kiliaan; Jurgen A H R Claassen
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-11       Impact factor: 6.200

Review 2.  Neuroradiological findings in vascular dementia.

Authors:  Ali Guermazi; Yves Miaux; Alex Rovira-Cañellas; Joyce Suhy; Jon Pauls; Ria Lopez; Holly Posner
Journal:  Neuroradiology       Date:  2006-11-18       Impact factor: 2.804

Review 3.  Vascular cognitive impairment: disease mechanisms and therapeutic implications.

Authors:  Deborah A Levine; Kenneth M Langa
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

4.  ApoE gene polymorphism and vascular dementia in Chinese population: a meta-analysis.

Authors:  Xu Liu; Lei Li; Fang Liu; Shuming Deng; Ruixia Zhu; Qu Li; Zhiyi He
Journal:  J Neural Transm (Vienna)       Date:  2011-10-09       Impact factor: 3.575

Review 5.  Animal Models of Vascular Cognitive Impairment and Dementia (VCID).

Authors:  Jennifer Gooch; Donna M Wilcock
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

6.  Treatment of vascular dementia: evidence from epidemiologic studies.

Authors:  Hee-Joon Bae; Dilip K Pandey
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

7.  Effect of electroacupuncture on the expression of mTOR and eIF4E in hippocampus of rats with vascular dementia.

Authors:  Yanzhen Zhu; Yanjun Zeng; Xuan Wang; Xiaobao Ye
Journal:  Neurol Sci       Date:  2012-10-09       Impact factor: 3.307

8.  Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.

Authors:  Gustavo C Román; Stephen Salloway; Sandra E Black; Donald R Royall; Charles Decarli; Michael W Weiner; Margaret Moline; Dinesh Kumar; Rachel Schindler; Holly Posner
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

Review 9.  Donepezil: in vascular dementia.

Authors:  David R Goldsmith; Lesley J Scott
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Neurobiol Aging       Date:  2008-03-04       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.